LSP Management Group

Evommune, Inc. develops and manufactures tissue-based medicines for inflammatory diseases. It offers medicines for immunology and dermatology. The company was incorporated in 2020 and is based in Los Altos, California.

Operator of a biopharmaceutical company intended to discover and develop therapies that slow or stop the progression of neurodegenerative diseases. The company engages in identifying new medicines to preserve cognition and other brain functions and enhance resilience to neurodegenerative diseases including Alzheimer's, Frontotemporal Dementia, and Parkinson's, enabling people suffering from neurodegenerative diseases to access suitable therapeutics for fast recovery.

New Amsterdam Pharma B.V. is a clinical-stage biopharmaceutical company based in Naarden, the Netherlands, focused on researching and developing innovative therapies for cardio-metabolic diseases. Founded in 2019, the company is dedicated to improving patient care for those with metabolic disorders, particularly where existing treatments are inadequate or poorly tolerated. Its lead product, obicetrapib, is a next-generation oral CETP inhibitor designed to provide a preferred LDL cholesterol-lowering option for patients who experience statin intolerance or for those with Arteriosclerotic Cardiovascular Disease and Familial Hypercholesterolemia who are on maximally tolerated statin therapy.

Lumeon Ltd. is a digital health company specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and headquartered in London, the company offers a cloud-based platform known as the Care Pathway Manager, which provides a comprehensive, real-time view of the patient journey from referral to outcome. Lumeon's services encompass business analysis, project management, data migration, training, and ongoing support. By focusing on the entire care pathway, Lumeon aids healthcare providers in optimizing clinical and administrative workflows, automating tasks, and achieving measurable healthcare outcomes. The company serves a diverse range of clients, including some of Europe's leading healthcare organizations. Lumeon was previously known as Qinec Ltd. before rebranding in July 2016.

Imcyse SA is a clinical-stage biotechnology company based in Liège, Belgium, established in 2010. The company focuses on developing active and specific immunotherapeutics aimed at treating and preventing severe chronic diseases linked to immune system disruptions. Its primary development program is ImotopeTM, which targets type 1 diabetes. In addition to diabetes, Imcyse is committed to creating disease-specific immune therapies for a range of conditions, including autoimmune, inflammatory, allergic, infectious diseases, and tumors. Through its innovative approach, Imcyse seeks to address significant unmet medical needs in the field of immunotherapy.

Lumeon Ltd. is a digital health company specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and headquartered in London, the company offers a cloud-based platform known as the Care Pathway Manager, which provides a comprehensive, real-time view of the patient journey from referral to outcome. Lumeon's services encompass business analysis, project management, data migration, training, and ongoing support. By focusing on the entire care pathway, Lumeon aids healthcare providers in optimizing clinical and administrative workflows, automating tasks, and achieving measurable healthcare outcomes. The company serves a diverse range of clients, including some of Europe's leading healthcare organizations. Lumeon was previously known as Qinec Ltd. before rebranding in July 2016.

Aelin Therapeutics NV is a Belgian biotherapeutics company founded in 2017, focused on developing antibiotics and therapeutics utilizing its innovative Pept-in technology. This technology leverages protein aggregation to achieve functional knockdown of target proteins, making it applicable against challenging conditions such as Methicillin-resistant Staphylococcus aureus (MRSA) and other undruggable targets in humans. Aelin Therapeutics was established as a collaboration between VIB and partner universities including KU Leuven, VUB, and UGent, building on the pioneering research of noted structural biologists. The company has compiled a robust preclinical proof of concept data package, demonstrating the diverse applications of its technology across various biological targets, including bacteria, cancer cells, fungi, viruses, and plant cells. Aelin Therapeutics differentiates itself through the unique mechanism of action of its Pept-in technology, which allows for the rational design of biotherapeutics that can target intracellular spaces often inaccessible to conventional small molecules or antibodies. The company is headquartered in Heverlee, Belgium.

Nouscom are a well established team that has worked together for many years in previous successful enterprises, including IRBM/Merck and Okairos, and are veterans in the field of oncolytic and genetic vaccines. The company is headquartered in Basel, Switzerland and has operations in Rome, Italy. The NousCom team is lead by experienced enterpreneurs that worked together for many years in previous successful enterprises, such as Okairos, under the leadership of Prof. Riccardo Cortese, who conceived the ideas behind those companies.

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.

Rainier Therapeutics, Inc., a biotechnology company, develops a targeted biologic for the potential treatment of early stage and metastatic bladder cancer. It offers Vofatamab (B-701), a human monoclonal antibody that targets and specifically blocks the activity of FGFR3 (fibroblast growth factor receptor 3) that is used for the treatment for metastatic bladder cancer. Rainier Therapeutics, Inc. was formerly known as BioClin Therapeutics, Inc. and changed its name to Rainier Therapeutics, Inc. in November 2018. The company was founded in 2010 and is based in San Leandro, California.

Immunic Therapeutics is a clinical-stage biopharmaceutical company focused on developing selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. Its primary product, IMU-838, is a selective immune modulator currently in Phase 2 clinical trials for ulcerative colitis, relapsing-remitting multiple sclerosis, and Crohn's disease. Additionally, the company is advancing IMU-935, an inverse agonist targeting RORgt, and IMU-856, which aims to restore intestinal barrier function in patients with conditions such as inflammatory bowel disease and irritable bowel syndrome. Immunic Therapeutics is headquartered in New York, New York, and seeks to provide effective treatment options for a range of chronic inflammatory conditions through its innovative drug development initiatives.

Luxendo will manufacture and sell advanced Single Plane Illumination Microscopes (SPIM) originally developed at EMBL by Lars Hufnagel and his team. SPIM is a rapidly emerging technology that combines optical sectioning with multiple-view imaging to observe tissues and living organisms with impressive resolution. Unlike the conventional techniques of widefield and confocal fluorescence microscopy, the light sheet technique illuminates on the region surrounding the focal plane of the detection objective in a twin objective configuration.

Ventaleon is developing inhaled treatments against viral infections. The Company’s lead therapy, is an inhaled LASAG (D,L-lysine acetylsalicylate • glycine), a lysin-salt formulation of well-known acetyl salicylic acid (Aspirin®), suitable as an ingredient for inhalable aerosol, has completed Phase II clinical trials to treat severe influenza. A proof-of-concept study in influenza patients with moderate to severe symptoms demonstrated more rapid symptom decline when administered via inhaled LASAG compared to standard of care. The Company is currently preparing to enter a pivotal clinical trial with inhaled LASAG. Ventaleon was founded as a spin-off from Activaero, a leading specialist in aerosol inhalation therapies and technologies, in 2012

Sequana Medical is a medical device company based in Zurich, Switzerland, specializing in implantable pump systems designed to manage fluid balance in the body. The company's flagship product, the alfapump, addresses ascites, the accumulation of fluid in the abdominal cavity often associated with advanced liver disease, certain cancers, and congestive heart failure. The alfapump system facilitates the automatic and continuous removal of ascites by transferring excess fluid to the bladder, where it is expelled naturally. Additionally, Sequana Medical offers the alfapump DSR, which targets sodium removal in patients experiencing volume overload due to heart failure. Founded in 2006 and with a strong presence in Germany, Sequana Medical aims to improve the quality of life for patients suffering from fluid overload conditions through innovative treatment solutions.

To this end, arGEN-X has invented and developed a breakthrough discovery platform setting the new standard for antibody lead choice in the discovery of human antibody therapeutics. Fuelled by the best possible natural immune responses available, our Simple Antibodyâ„¢ platform leapfrogs existing platforms in what is probably the most critical aspect of drug discovery and development: lead choice.

Activaero GmbH, a drug delivery company, engages in the research, development, manufacture, and marketing of controlled breathing technologies that are used for the delivery of inhaled therapeutic agents to the human lung and various lung regions. It offers AKITA, a controlled breathing device with smart card technology for the pulmonary delivery of inhaled therapeutics; and Watchhaler, an inhalation device tailored to the needs of children who need to take inhaled medication. The company also provides AKITA², a controlled breathing technology for the pulmonary delivery of inhaled therapeutics in the clinical trial setting; and LimiX, a first flow limitation valve that controls the flow rate. In addition, it offers measurement and diagnostic technologies for use in laboratory settings, including a system to measure the properties of aerosols in a minute. Further, the company provides contract development services for devices to use in clinical trials; and clinical trial logistics services. It markets its products through distributors. Activaero GmbH was founded in 2004 and is based in Gemunden, Germany. It also has locations in Munich, Germany; and Dublin, Ohio.

Syntaxin is a biopharmaceutical company that engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases. The biopharmaceutical company's proprietary technology platform enables the engineering of bacterial proteins by domain substitution, to produce novel cell-specific biotherapeutics that inhibit cell secretion. These products can have therapeutic effects in a wide range of indications.

Pasteuria Bioscience, Inc. was founded in 2003 in the University of Florida's Sid Martin Biotechnology Incubator. The company was developed out of Entomos, Inc., to commercialize its revolutionary technology for production of nematode control products Pasteuria Bioscience has successfully raised over $6 million in venture funding in its series A and series B rounds, which has enabled the advancement of the technology to the point of commercial-scale production and EPA registration of its first product. This initial product will be for control of sting nematodes in professional turf, and is expected to launch in late 2009. Progress towards launch is supported by multiple ongoing turf field trials and other commercial development activities. The company also continues to build its pipeline of products and its intellectual property portfolio through a vigorous laboratory development program.

Efficas Medical Foods & Nutrition, LLC is a health-science and technology company focused on researching, developing, and commercializing products aimed at the nutritional management of the immune system for both humans and pets. The company offers Efficas Care, a berry-flavored non-prescription medical food designed to help manage asthma and associated allergies. Established in 2010 and based in Fullerton, California, Efficas is committed to providing effective nutritional solutions to enhance health and well-being.

KuDOS Pharmaceuticals Ltd discovers and develops drugs based upon the science of DNA damage sensing, signaling, and repair to address medical needs in cancer treatment.